Pericentrin deficiency in smooth muscle cells augments atherosclerosis through HSF1-driven cholesterol biosynthesis and PERK activation
JCI Insight · 08.11.2023 · 8 (21)
DOI: 10.1172/jci.insight.173247 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCI Insight, online erschienen am 08.11.2023. Verfasst von Suravi Majumder und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Genetics, Department of Internal Medicine, McGovern Medical School, and. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Atherosclerosis, Plaque, Atherosclerotic. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NHGRI NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
Microcephalic osteodysplastic primordial dwarfism type II (MOPDII) is caused by biallelic loss-of-function variants in pericentrin ( PCNT ), and premature coronary artery disease (CAD) is a complication of the syndrome. Histopathology of coronary arteries from patients with MOPDII who died of CAD in their 20s showed extensive atherosclerosis. Hyperlipidemic mice with smooth muscle cell–specific (SMC-specific) Pcnt deficiency ( Pcnt SMC–/– ) exhibited significantly greater atherosclerotic plaque burden compared with similarly treated littermate controls despite similar serum lipid levels. Loss of PCNT in SMCs induced activation of heat shock factor 1 (HSF1) and consequently upregulated the expression and activity of HMG-CoA reductase (HMGCR), the rate-limiting enzyme in cholesterol biosynthesis. The increased cholesterol biosynthesis in Pcnt SMC–/– SMCs augmented PERK signaling and phenotypic modulation compared with control SMCs. Treatment with the HMGCR inhibitor, pravastatin, blocked the augmented SMC modulation and reduced plaque burden in hyperlipidemic Pcnt SMC–/– mice to that of control mice. These data support the notion that Pcnt deficiency activates cellular stress to increase SMC modulation and plaque burden, and targeting this pathway with statins in patients with MOPDII has the potential to reduce CAD in these individuals. The molecular mechanism uncovered further emphasizes SMC cytosolic stress and HSF1 activation as a pathway driving atherosclerotic plaque formation independently of cholesterol levels.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Medical Genetics, Department of Internal Medicine, McGovern Medical School, and.
- Department of Pathology and Laboratory Medicine, The University of Texas Health Science Center at Houston, Houston, Texas, USA.
Förderung
- NIGMS NIH HHS
- NHGRI NIH HHS
- NHLBI NIH HHS
- NIDDK NIH HHS
Zitieren
APA
Majumder, S., Chattopadhyay, A., Wright, J. M., Guan, P., Buja, L. M., Kwartler, C. S., & Milewicz, D. M. (2023). Pericentrin deficiency in smooth muscle cells augments atherosclerosis through HSF1-driven cholesterol biosynthesis and PERK activation. JCI Insight, 8(21). https://doi.org/10.1172/jci.insight.173247
Vancouver
Majumder S, Chattopadhyay A, Wright JM, Guan P, Buja LM, Kwartler CS, et al. Pericentrin deficiency in smooth muscle cells augments atherosclerosis through HSF1-driven cholesterol biosynthesis and PERK activation. JCI Insight. 2023;8(21). doi:10.1172/jci.insight.173247
BibTeX
@article{Majumder2023,
author = {Majumder, Suravi and Chattopadhyay, Abhijnan and Wright, Jamie M and Guan, Pujun and Buja, L Maximilian and Kwartler, Callie S and Milewicz, Dianna M},
title = {Pericentrin deficiency in smooth muscle cells augments atherosclerosis through HSF1-driven cholesterol biosynthesis and PERK activation},
journal = {JCI Insight},
year = {2023},
volume = {8},
number = {21},
doi = {10.1172/jci.insight.173247}
}
EUVIMED